Companies co-founded.
Hillman Ventures
Founded 1995. Dallas. Private family office investing personal capital in FDA-regulated frontier biotech. Active. Read Andrew Hillman, Principal of Hillman Ventures.
Affinity Healthcare Systems Inc
2007 to 2010. Co-founder. FDA-regulated specialty healthcare services. Exited to Dynacq Healthcare (NASDAQ: DYII).
PPM Rehabilitation
2011 to 2016. Co-founder. Rehabilitation services platform. Exited to Next Health.
Advanced Total Management
2012 to 2017. Co-founder. Pharmaceutical wholesale distribution. Exited to 
Next Health (LinkedIn).
Infinity Toxicology LLC
2012 to 2020. Co-founder. CLIA Highly Complex toxicology laboratory. Exited to Critical Healthcare Ltd, UK.
Apothecary Shop Pharmacy
2007 to 2014. Co-founder. Specialty pharmacy services. Exited to 
Pharma Holdings U.S.
Dallas Claims Assistance
1998 to 2005. Co-founder. Healthcare claims processing. Exited to The Alpha Group (TAG).
Current focus areas
Mesenchymal exosome biologics on the 351(a) BLA pathway. Targeted Osmotic Lysis for solid tumors with
an academic medical foundation.
Exosome and mesenchymal stem cell derived extracellular vesicle products are not approved by the FDA for any indication. References here describe published scientific literature. They do not describe an available treatment. Targeted Osmotic Lysis is investigational. It has not been approved by the FDA for any indication and it is not available as a treatment.